CERo Therapeutics Holdings, Inc. (CERO)
OTCMKTS · Delayed Price · Currency is USD
0.0475
-0.0025 (-5.00%)
At close: Jan 30, 2026
CERo Therapeutics Holdings Employees
CERo Therapeutics Holdings had 8 employees as of December 31, 2024. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$6,148,877
Market Cap
1.19M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 8 | -1 | -11.11% | 8 | 0 |
| Dec 31, 2023 | 9 | - | - | 8 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Emmaus Life Sciences | 35 |
| International Stem Cell | 32 |
| Evofem Biosciences | 32 |
| ZyVersa Therapeutics | 7 |
| Lipella Pharmaceuticals | 7 |
| Sigyn Therapeutics | 4 |
| Galera Therapeutics | 3 |
CERo Therapeutics Holdings News
- 25 days ago - CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML - GlobeNewsWire
- 6 weeks ago - CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1) - GlobeNewsWire
- 2 months ago - CERo Therapeutics Announces Trading on OTCQB Market - GlobeNewsWire
- 3 months ago - CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing - GlobeNewsWire
- 3 months ago - CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response - GlobeNewsWire
- 3 months ago - CERo Therapeutics Announces Receipt of Nasdaq Panel Determination - GlobeNewsWire
- 3 months ago - CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML - GlobeNewsWire
- 3 months ago - CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025 - GlobeNewsWire